Steven Triesenberg
Internal Medicine · Grand Rapids, MINPI 1588645139
Payments from drug & device makers
Across 179 payments — averaging $97.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Amgen$2K
- Novo Nordisk$354
- AstraZeneca$157
- Esperion Therapeutics, Inc.$143
- GSK$133
- plus $812 from 18 others
What the payments were for
- Speaking & faculty fees$12,20070%
- Travel & lodging$1,0506%
- Food & beverage$4,16924%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $14,083 |
| Amgen | 100 | $1,757 |
| Novo Nordisk | 7 | $354 |
| AstraZeneca(2 entities) | 3 | $157 |
| Esperion Therapeutics, Inc. | 2 | $143 |
| GSK | 7 | $133 |
| Lilly USA, LLC | 2 | $125 |
| Antares Pharma, Inc. | 6 | $111 |
| Eisai Inc. | 4 | $102 |
| Novartis | 4 | $88 |
| Dexcom, Inc. | 4 | $77 |
| Pfizer | 2 | $41 |
| Vertex | 1 | $35 |
| International Rehabilitative Sciences, Inc | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $24 |
| Heartflow, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Exact Sciences | 1 | $21 |
| IBSA Pharma Inc. | 1 | $20 |
| Abiomed | 1 | $19 |
| Tolmar, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,440 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 50 | $38,328 |
| EliquisApixaban | 20 | $20,656 |
| OzempicSemaglutide | 14 | $18,313 |
| JardianceEmpagliflozin | 12 | $17,868 |
| Repatha SyringeEvolocumab | 13 | $6,752 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,007 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 17 | $3,100 |
| Vivelle-DotEstradiol | 13 | $1,907 |
| Rosuvastatin Calcium | 87 | $1,805 |
| Atorvastatin Calcium | 70 | $1,321 |
| Tamsulosin Hcl | 49 | $1,117 |
| Losartan Potassium | 54 | $976 |
| Testosterone Cypionate | 15 | $846 |
| Celecoxib | 28 | $805 |
| Levothyroxine Sodium | 48 | $804 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $41 | $20,65620 claims |
| Novo NordiskOzempic | $354 | $18,31314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Grand Rapids
- Leslie PelkeyGrand Rapids$8.5M
- Khan NeddGrand Rapids$2.2M
- Robert SelfeGrand Rapids$238K
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.